- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | What Analysts Are Saying About TScan Therapeutics Stock | 4 | Benzinga.com | ||
| 07.05. | H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating | 2 | Investing.com | ||
| 06.05. | TScan Therapeutics GAAP EPS of $0.26 | 5 | Seeking Alpha | ||
| 06.05. | TScan Therapeutics May 2025 slides: advancing TCR-T therapies with positive Phase 1 data | 2 | Investing.com | ||
| 06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 08.04. | Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
| 27.03. | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
| 06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
| 05.03. | TScan Therapeutics files for $300M mixed securities shelf | 2 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
| 05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.08.24 | TScan Therapeutics, Inc.: TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 206 | GlobeNewswire (Europe) | FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| MEDIGENE | 0,125 | -10,71 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
| BIOFRONTERA | 2,280 | 0,00 % | Biofrontera AG: Verhandlungen mit Biofrontera Inc. gehen kommende Woche weiter | Bad Marienberg (www.anleihencheck.de) - Pressemitteilung der Biofrontera AG vom 26.06.2025:Die Verhandlungen zwischen der deutschen Biofrontera Gruppe und dem US-amerikanischen Unternehmen Biofrontera... ► Artikel lesen | |
| BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
| EDITAS MEDICINE | 1,924 | -1,00 % | Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? | ||
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| GALAPAGOS NV | 24,160 | +1,00 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| IMMATICS | 4,700 | +1,42 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
| AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,990 | +0,51 % | Autolus Therapeutics plc - 8-K, Current Report | ||
| IGM BIOSCIENCES | 1,010 | +1,00 % | IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs | - Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December... ► Artikel lesen | |
| ONCOPEPTIDES | 0,129 | +9,31 % | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides AB (publ) | Stockholm, Sweden - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
| AVACTA | 0,340 | +0,59 % | AVACTA GROUP PLC: Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives | AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 ... ► Artikel lesen |
TSCAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,050 (-3,38 %) liegt der Kurs bei 1,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TSCAN THERAPEUTICS INC finden Sie auf Wallstreet Online.